Home » Stocks » MTEM

Molecular Templates, Inc. (MTEM)

Stock Price: $11.09 USD 0.66 (6.33%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $11.25 +0.16 (1.44%) Mar 5, 7:00 PM
Market Cap 620.64M
Revenue (ttm) 21.55M
Net Income (ttm) -92.35M
Shares Out 49.03M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $11.09
Previous Close $10.43
Change ($) 0.66
Change (%) 6.33%
Day's Open 10.55
Day's Range 10.21 - 11.12
Day's Volume 452,304
52-Week Range 7.51 - 18.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 6 days ago

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases th...

Other stocks mentioned: ADC, CAR, ZTS, AAT, INCY, OPK, RPRX, SONO, USLM
Benzinga - 2 weeks ago

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented t...

Other stocks mentioned: BMBL, FISV, ATEX, CRVS, DBTX, NEXI, ONCR, PRTA, TLIS
Benzinga - 2 weeks ago

Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly ow...

Other stocks mentioned: NVTA, VERU, CYH
GlobeNewsWire - 2 weeks ago

AUSTIN, Texas, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery an...

GlobeNewsWire - 3 weeks ago

Molecular Templates to receive $70 million upfront payment with potential for additional milestone and royalty payments on future sales Molecular Templates to receive $70 million upfront payme...

GlobeNewsWire - 2 months ago

Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types...

GlobeNewsWire - 3 months ago

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery ...

GlobeNewsWire - 4 months ago

AUSTIN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on...

GlobeNewsWire - 6 months ago

AUSTIN, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discove...

GlobeNewsWire - 7 months ago

AUSTIN, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused ...

GlobeNewsWire - 7 months ago

AUSTIN, Texas, July 20, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused ...

GlobeNewsWire - 8 months ago

Update Provided Phase I Study of MT-5111 in HER2-positive Cancers

Seeking Alpha - 8 months ago

Molecular Templates: Updates To Thesis, Pursuing Validated Targets With Unique MOA

GlobeNewsWire - 9 months ago

AUSTIN, Texas, May 22, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused o...

Zacks Investment Research - 10 months ago

As of late, it has definitely been a great time to be an investor Molecular Templates

Zacks Investment Research - 11 months ago

Take advantage of panic selling with these 7 cheap stocks.

Other stocks mentioned: APAM, BCRX, CALX, OESX, SPN, TRN
GlobeNewsWire - 1 year ago

Milestone Triggers $10 Million Payment to Molecular Templates Milestone Triggers $10 Million Payment to Molecular Templates

GlobeNewsWire - 1 year ago

Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from Internal Research and Partnerships Three Products Advancing in the Clinic with Additional Pipeline Growth to...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company...

The Motley Fool - 1 year ago

New drugs from these companies seek to enable more patients to receive cutting-edge cell and gene therapies.

Other stocks mentioned: MGTA
GlobeNewsWire - 1 year ago

AUSTIN, Texas, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery ...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery ...

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’...

Seeking Alpha - 1 year ago

Shares have risen by 20% since my initial article.

GlobeNewsWire - 1 year ago

AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company...

Zacks Investment Research - 1 year ago

Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Shares have risen as a result of optimism regarding Takeda partnership and advancing ETB pipeline.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Molecular Templates.

Zacks Investment Research - 1 year ago

Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About MTEM

Molecular Templates, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies. The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 tar... [Read more...]

Industry
Biotechnology
CEO
Eric Poma
Employees
228
Stock Exchange
NASDAQ
Ticker Symbol
MTEM
Full Company Profile

Financial Performance

In 2019, MTEM's revenue was $22.27 million, an increase of 67.63% compared to the previous year's $13.29 million. Losses were -$69.42 million, 129.2% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for MTEM stock is "Strong Buy." The 12-month stock price forecast is 19.25, which is an increase of 73.58% from the latest price.

Price Target
$19.25
(73.58% upside)
Analyst Consensus: Strong Buy